Merck & Co. Inc. (MRK) Rises 1.58% After Earnings

2026-02-03 · Stocks · QuoteReporter

Post Earning Analysis

Merck & Co. Inc. (MRK) Rises 1.58% After Earnings

Merck & Co., Inc., a prominent health care company founded in 1891 and headquartered in Rahway, New Jersey, specializes in delivering comprehensive health solutions. It operates through its Pharmaceutical, Animal Health, and Other segments, offering a broad range of prescription medicines, vaccines, biologic therapies, and consumer care products. Merck is dedicated to improving health outcomes with its innovative treatments for both humans and animals.

The current price of the asset is $115.89, showing a notable increase of 1.58% today. This price is near its 52-week and year-to-date high of $118.45, suggesting a strong upward trend in the short term. The asset has significantly outperformed its 52-week and year-to-date low of $71.26, reflecting a robust gain of over 62% from these lows, indicating strong bullish momentum throughout the year.

The price is currently above all key moving averages (MA20, MA50, MA200), with increases of 5.58%, 10.52%, and 33.11% respectively, which signals a strong upward trend and positive sentiment among investors. The week’s low and high show a volatility range, with the price rebounding effectively from the lower boundary.

The Relative Strength Index (RSI) at 70.62 is nearing the overbought threshold of 70, suggesting potential for a price pullback or stabilization. The Moving Average Convergence Divergence (MACD) at 2.1 also supports the strength of the current bullish trend. However, both indicators hint at caution due to the proximity to overbought conditions, potentially leading to a short-term consolidation or correction.

Merck & Co., Inc. reported its Q4 2025 financial results, showcasing a year of robust performance, particularly in its oncology and animal health segments. For the fourth quarter, the company achieved worldwide sales of $16.4 billion, marking a 5% increase year-over-year, with a notable 4% growth when excluding the impact of foreign exchange. The full-year sales reached $65.0 billion, a modest rise of 1% from the previous year, with a 2% increase on a constant currency basis.

The GAAP earnings per share (EPS) for Q4 were $1.19, reflecting a 20% decrease from Q4 2024, while the non-GAAP EPS rose by 19% to $2.04. The full-year GAAP EPS was $7.28, up 8% from 2024, and the non-GAAP EPS increased by 17% to $8.98.

Key product sales included KEYTRUDA and KEYTRUDA QLEX, which collectively generated $8.37 billion in Q4, and WINREVAIR, which saw a significant 133% growth. However, GARDASIL sales declined by 34% year-over-year.

Merck also highlighted a 45% increase in Q4 cost of sales and a 15% reduction in research and development expenses. The company anticipates worldwide sales for the next year to be between $65.5 billion and $67.0 billion and projects a non-GAAP EPS range of $5.00 to $5.15. Notably, Merck did not declare a quarterly dividend or announce any share repurchase programs in this report.

Earnings Trend Table

The examination of the EPS (Earnings Per Share) trends over the observed quarters reveals a consistent pattern of positive surprises where the reported EPS consistently exceeds the estimated EPS. This trend suggests robust financial performance relative to analyst expectations, which could be indicative of the company’s operational efficiency and potentially conservative forecasting by analysts.

Starting from April 2024, the company reported an EPS of 2.07 against an estimate of 1.88, marking a substantial surprise of 10.40%. This trend of exceeding expectations continued in subsequent quarters. For instance, in July 2024, the reported EPS was 2.28 compared to the estimate of 2.15, resulting in a surprise of 5.83%. The pattern persisted with the October 2024 EPS at 1.57 versus an estimate of 1.50 (surprise of 4.39%), and in February 2025, where the EPS of 1.72 surpassed the estimate of 1.62 by 6.50%.

The most recent data from April 2025 shows a reported EPS of 2.22 against an estimate of 2.14, with a surprise of 3.96%. This consistent outperformance in EPS across all reported quarters not only highlights the company’s ability to surpass financial expectations but also might influence investor confidence positively, reflecting a potentially strong market outlook for the company.

Dividend Payments Table

The provided dividend data indicates a clear upward trend in the payouts over the observed periods. Starting from March 2024, dividends were consistently set at $0.77 per share for three consecutive quarters. A notable increase occurred in September 2024, where dividends rose to $0.81 per share, suggesting a strategic adjustment possibly in response to improved company performance or a revised shareholder return policy.

This increased dividend rate of $0.81 was maintained through the subsequent four quarters, reflecting stability in the company’s dividend policy and possibly steady cash flows or earnings. The latest data point from December 2025 shows a further increase to $0.85 per share, marking the highest dividend payout in the available dataset. This increment could be indicative of continued positive financial health and a commitment to returning value to shareholders.

Overall, the trend suggests a healthy financial position of the company, with progressive increases in dividend payouts pointing towards optimistic future prospects.

The four most recent rating changes in the financial sector present a positive outlook for the subject entity, as evidenced by upgrades from multiple reputable research firms.

1. Wolfe Research on January 8, 2026: Wolfe Research upgraded their rating from “Peer Perform” to “Outperform” with a target price set at $135. This upgrade suggests a bullish stance on the entity’s performance, indicating expectations of the entity outperforming its peers or the sector average.

2. BMO Capital Markets on December 18, 2025: BMO Capital Markets also shifted their position, upgrading from “Market Perform” to “Outperform” and setting a target price of $130. This adjustment implies that BMO Capital sees a strong potential for growth in the entity, surpassing the general market performance.

3. Wells Fargo on November 24, 2025: Wells Fargo upgraded their rating from “Equal Weight” to “Overweight” with a target price of $125. The “Overweight” rating indicates that Wells Fargo advises a higher investment in this entity relative to other investments in the portfolio, based on anticipated performance.

4. Scotiabank on November 13, 2025: Scotiabank initiated coverage with a “Sector Outperform” rating and a target price of $105. This initiation at a positive rating suggests Scotiabank’s confidence in the entity’s capability to excel within its sector.

Collectively, these upgrades and positive initiations reflect a robust confidence among financial analysts regarding the future performance of the entity. The increasing target prices, ranging from $105 to $135, underscore a consensus on the entity’s potential for value growth, making it a noteworthy contender for investors seeking exposure in its respective sector.

The current price of the stock stands at $115.89. Recent analyses from various research firms have set higher target prices, indicating a positive outlook. Wolfe Research upgraded its rating and set a target price at $135, suggesting significant growth potential. Similarly, BMO Capital Markets upgraded their view and set a target price at $130. Wells Fargo also showed optimism by upgrading their rating and setting the target at $125. The lowest among the recent target prices comes from Scotiabank, which initiated coverage with a target of $105, still below the current market price but indicative of a generally favorable view.

This consensus among top analysts suggests a robust upward trajectory for the stock, with the average target price from the latest ratings being approximately $123.75, which is about 6.8% higher than the current stock price. This trend indicates a strong confidence in the stock’s future performance, potentially driven by positive earnings per share (EPS) and dividend trends, although specific EPS and dividend data were not provided.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.